Westmore · UDRP DecisionAmgenpet.com
The Panel ordered transfer of <amgenpet.com> after finding it confusingly similar to the Complainant’s AMGEN mark, finding no rights or legitimate interests on the unrebutted record, and concluding that the Respondent’s registration and passive holding constituted bad faith in the circumstances, including the distinctive and well-known character of AMGEN and the presumed awareness of the Complainant’s rights.
The timeline behind amgenpet.com
Registration, the decision and the archived record of what this domain actually displayed — from public RDAP and the Internet Archive.
Westmore reconstructs the full history behind amgenpet.com — from public RDAP and the Internet Archive — as part of UDRP Intelligence:
The case illustrates a transfer based on passive holding where the domain wholly incorporated an invented, distinctive, and well-known mark, the registrant offered no legitimate explanation, and the surrounding circumstances supported presumed awareness and opportunistic bad faith. It also shows that adding a descriptive English word did not avoid confusing similarity.
Result of record. The panel's reasoning and decisive facts behind each element are in the Intelligence dossier below.
WIPO Arbitration and Mediation Center ADMINISTRATIVE PANEL DECISION Amgen, Inc. v. He Nan An Jin Sheng Wu Ji Shu Gu Fen You Xian Gong Si Case No. D2019-1221 1. The Parties The Complainant is Amgen, Inc., United States of America (“United States”), represented by McDermott Will & Emery LLP, United States. The Respondent is He Nan An Jin Sheng Wu Ji Shu Gu Fen You Xian Gong Si, China. 2. The Domain Name and Registrar The disputed domain name <amgenpet.com> is registered with Alibaba Cloud Computing (Beijing) Co., Ltd. (the “Registrar”). 3. Procedural History The Complaint in English was filed with the WIPO Arbitration and Mediation Center (the “Center”) on May 28, 2019. On May 29, 2019, the Center transmitted by email to the Registrar a request for registrar verification in connection with the disputed domain name. On May 30, 2019, the Registrar transmitted by email to the Center its verification response disclosing registrant and contact information for the disputed domain name which differed from the named Respondent and contact information in the Complaint. The Center sent an email communication to the Complainant on May 31, 2019 providing the registrant and contact information disclosed by the Registrar, and inviting the Complainant to submit an amendment to the Complaint. The Complainant filed an amended Complaint in English on June 5, 2019. On May 31, 2019, the Center transmitted an email in English and Chinese to the Parties regarding the language of the proceeding. The Complainant requested that English be the language of the proceeding on On June 3, 2019. The Respondent did not comment on the language of the proceeding. The Center verified that the Complaint together with the amended Complaint satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy” or “UDRP”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”). In accordance with the Rules, paragraphs 2 and 4, the Center formally notified the Respondent in English and Chinese of the Complaint, and the proceedings commenced on June 11, 2019. In accordance with the Rules, paragraph 5, the due date for Response was July 1, 2019. The Respondent did not submit any response. Accordingly, the Center notified the Respondent’s default on July 3, 2019. The Center appointed Sok Ling MOI as the sole panelist in this matter on July 8, 2019. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7. 4. Factual Background The Complainant is a global biopharmaceutical company focused on research, innovation and treatment in the areas of cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. The Complainant has offered a range of goods and services under the AMGEN trade mark since as early as 1981. The Complainant operates in approximately 100 countries and employs approximately 20,000 staff worldwide. The Complainant owns registrations for the AMGEN trade mark for various biopharmaceutical goods and services, including the following: Jurisdiction Trade Mark Class Registration Number Registration Date United States AMGEN 5, 42 1,621,967 November 13, 1990 United States AMGEN 5 2,170,735 July 7, 1998 United States AMGEN 5, 10, 35, 36, 41, 42, 44 3,226,919 April 10, 2007 United States AMGEN 5 3,921,146 February 15, 2011 The Complainant also owns the domain name <amgen.com> and has used it to offer and promote its biopharmaceutical goods and services for the past 18 years. The Respondent registered the disputed domain name <amgenpet.com> on September 12, 2018. According to evidence submitted by the Complainant, the disputed domain name does not resolve to any active website but is being passively held. 5. Parties’ Contentions A. Complainant The Complainant contends that the disputed domain name is identical or confusingly similar to its trade mark AMGEN, the Respondent has no rights or legitimate interests in respect of the disputed domain name, and the disputed domain name has been registered and is being used in bad faith. The Complainant requests for the transfer of the disputed domain name. B. Respondent The Respondent did not reply to the Complainant’s contentions. 6. Discussion and Findings 6.1. Language of the Proceeding Pursuant to paragraph 11(a) of the Rules, unless otherwise agreed by the Parties, or specified otherwise in the Registration Agreement, the language of the administrative proceeding shall be the language of the Registration Agreement, subject to the authority of the Panel to determine otherwise, having regard to the circumstances of the administrative proceeding. Paragraph 10(b) and (c) of the Rules requires the Panel to ensure that the proceeding takes place with due expedition and that the Parties are treated fairly and given a fair opportunity to present their respective case. The language of the Registration Agreement for the disputed domain name is Chinese. From the evidence on record, no agreement appears to have been entered into between the Complainant and the Respondent regarding the language issue. The Complainant filed its Complaint in English and has requested that English be the language of the proceeding. On the record, the Respondent appears to be a Chinese company. However, the Panel finds persuasive evidence in the present proceeding to suggest that the Respondent has knowledge of English. In particular, the Panel notes that: (a) The disputed domain name <amgenpet.com> is registered in Latin characters, rather than Chinese script; (b) The disputed domain name consists of the English word “pet”; (c) The Center has notified the Respondent of the proceeding in both Chinese and English; (d) The Respondent has been given the opportunity to present its case in this proceeding and to respond to the issue of the language of the proceeding but has failed to do so; and (e) The Center has informed the Respondent that it would accept a response in either English or Chinese. The Panel finds the choice of English as the language of the present proceeding is fair to both Parties and is not prejudicial to either one of the Parties in his or her ability to articulate the arguments for this case. The Panel is also of the view that to require the Complaint and all supporting documents to be translated into in Chinese would in the circumstances of this case cause an unnecessary cost burden to the Complainant and unfairly disadvantage the Complainant. The proceeding would be unnecessarily delayed. Having considered all the matters above, the Panel determines under paragraph 11(a) of the Rules that (i) it shall accept the Complaint and all supporting materials as filed in English; and (ii) English shall be the language of the proceeding and the decision will be rendered in English. 6.2 Substantive Matters Paragraph 4(a) of the Policy directs that the complainant must prove each of the following three elements to obtain an order for the disputed domain name to be cancelled or transferred: (i) the disputed domain name registered by the respondent is identical or confusingly similar to a trade mark or service mark in which the complainant has rights; (ii) the respondent has no rights or legitimate interests in respect of the disputed domain name; and (iii) the disputed domain name has been registered and is being used in bad faith. On the basis of the evidence introduced by the Complainant, the Panel concludes as follows: A. Identical or Confusingly Similar The Panel accepts that the Complainant has trade mark rights in AMGEN by virtue of use and registration. The disputed domain name incorporates the Complainant’s trade mark AMGEN in its entirety. The addition of the descriptive word “pet” does not negate a finding of confusingly similarity between the disputed domain name and the Complainant’s trade mark. The addition of the generic Top-Level Domain (“gTLD”) “.com” is generally disregarded for the purpose of the similarity assessment. Consequently, the Panel finds that the disputed domain name is confusingly similar to the Complainant’s trade mark. Accordingly, the Complainant has satisfied the requirements of the first element under paragraph 4(a) of the Policy. B. Rights or Legitimate Interests Under paragraph 4(a)(ii) of the Policy, the complainant bears the burden of establishing that the respondent lacks rights or legitimate interests in the disputed domain name. However, once the complainant makes a prima facie showing under paragraph 4(a)(ii), the burden of production shifts to the respondent to establish its rights or legitimate interests in the disputed domain name by demonstrating any of the following, without limitation, under paragraph 4(c) of the Policy: (i) before any notice to it of the dispute, the respondent’s use of, or demonstrable preparations to use, the disputed domain name or a name corresponding to the disputed domain name in connection with a bona fide offering of goods or services; or (ii) the respondent has been commonly known by the disputed domain name, even if it has acquired no trade mark or service mark rights; or (iii) the respondent is making a legitimate noncommercial or fair use of the disputed domain name, without intent for commercial gain to misleadingly divert consumers or to tarnish the trade mark or service mark at issue. (See Taylor Wimpey PLC, Taylor Wimpey Holdings Limited v. honghao internet foshan co, ltd , WIPO Case No. D2013-0974 .) The Respondent’s name does not bear any resemblance to the term “amgen” or “pet”. There is no evidence suggesting that the Respondent is commonly known by the disputed domain name or that it has any rights in the term “amgen”. The Complainant has confirmed that the Respondent is not in any way related to or affiliated with the Complainant or otherwise authorized or licensed to use the AMGEN trade mark or to seek registration of any domain name incorporating the trade mark. According to evidence submitted by the Complainant, the disputed domain name does not resolve to any active website. There is no evidence to suggest that the Respondent has made any preparations to use the disputed domain name in connection with a bona fide offering of goods or services or for a legitimate noncommercial purpose. The Panel is therefore satisfied that the Complainant has made out a prima facie caseshowing that the Respondent lacks rights or legitimate interests in the disputed domain name. The burden of production thus shifts to the Respondent to establish its rights or legitimate interests in the disputed domain name. Since the Respondent has failed to respond, the prima facie case has not been rebutted. Consequently, the Panel finds that the Respondent lacks rights or legitimate interests in the disputed domain name. Accordingly, the Complainant has satisfied the requirements of the second element under paragraph 4(a) of the Policy. C. Registered and Used in Bad Faith Paragraph 4(b) of the Policy sets out four circumstances which, without limitation, shall be evidence of the registration and use of a disputed domain name in bad faith, namely: (i) circumstances indicating that the respondent has registered or acquired the disputed domain name primarily for the purpose of selling, renting, or otherwise transferring the domain name registration to the complainant who is the owner of the trade mark or service mark or to a competitor of the complainant, for valuable consideration in excess of the respondent’s documented out-of-pocket costs directly related to the disputed domain name; or (ii) the respondent has registered the disputed domain name in order to prevent the owner of the trade mark or service mark from reflecting the mark in a corresponding domain name, provided that the respondent has engaged in a pattern of such conduct; or (iii) the respondent has registered the disputed domain name primarily for the purpose of disrupting the business of a competitor; or (iv) by using the disputed domain name, the respondent has intentionally attempted to attract, for commercial gain, Internet users to the respondent’s website or other online location, by creating a likelihood of confusion with the complainant’s mark as to the source, sponsorship, affiliation, or endorsement of the respondent’s website or location or of a product or service on the respondent’s website or location. Being an invented name, AMGEN is indeed distinctive. The Panel accepts that the Complainant’s trade mark has become well-known worldwide as a result of extensive use over the past 35 years. A cursory Internet search would have disclosed the AMGEN trade mark and its extensive use by the Complainant. Thus a presumption arises that the Respondent was aware of the Complainant’s AMGEN trade mark and website when it registered the disputed domain name. Registration of a domain name that incorporates a complainant’s distinctive and well-known trade mark suggests opportunistic bad faith. The Panel notes that, as of the date of this decision, the disputed domain name <amgenpet.com> does not resolve to any active website. Nevertheless, the consensus view of previous UDRP panels is that passive holding in itself does not preclude a finding of bad faith. The UDRP panels must examine all the circumstances of the case to determine whether a respondent is acting in bad faith. See WIPO Overview of WIPO Panel Views on Selected UDRP Questions, Third Edition (“WIPO Overview 3.0 ”), section 3.3. The Respondent has not denied the Complainant’s allegations of bad faith. In view of the above finding that the Respondent does not have rights or legitimate interests in the disputed domain name, and taking into account all the circumstances, the Panel concludes that the Respondent has registered and used the disputed domain name in bad faith. Accordingly, the Complainant has satisfied the requirements of the third element under paragraph 4(a) of the Policy. 7. Decision For the foregoing reasons, in accordance with paragraphs 4(i) of the Policy and 15 of the Rules, the Panel orders that the disputed domain name <amgenpet.com> be transferred to the Complainant. Sok Ling MOI Sole Panelist Date: July 24, 2019
Source of record: WIPO . Reproduced for research; WIPO is the authoritative source.
What Westmore sees around amgenpet.com
The decision is only the record. Westmore connects it to the cases, authorities, panelists, parties and domain evidence surrounding it.
A short, grounded explanation drawn only from this decision's record — not legal advice or a prediction.
Grounded in the Westmore record for this decision. Research/informational only — not legal advice or a prediction of any outcome.
The decision is only the beginning.
You've seen what happened. Now discover the deeper intelligence behind the case, the panelist, the parties and the authorities that matter.
Go beyond the public record: see how this case has been cited, find comparable decisions, analyze the panelist and apply the relevant authorities to your Matter.
Westmore Professional · $395/month
Research with UDRP IntelligenceWestmore AI drafts an attorney-review-ready UDRP response from your facts, grounded in the exact panel and closest precedent.
$895 one-time per matter · no subscription required. Self-help drafting aid — not legal advice.
Build your responseWestmore UDRP records draw on WIPO-indexed decisions and are provided for research and informational purposes only. Not legal advice, a clearance opinion, or a prediction of any outcome.